Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis
Clinical Lymphoma Myeloma and Leukemia · 2026-11 · 26 (11) · e1241-e1248.e1
DOI: 10.1016/j.clml.2026.09.009 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Hosana Candreva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rio de Janeiro State University, Rio de Janeiro, Brazil. Electronic address: hosanaminac@gmail.com. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Watchful Waiting, Rituximab, Antineoplastic Agents, Immunological. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
The optimal initial management of asymptomatic patients with advanced-stage low-tumor-burden follicular lymphoma (LTB-FL) remains uncertain. Although watchful waiting (WW) has historically been the standard approach, rituximab monotherapy has emerged as an alternative strategy. A systematic review and meta-analysis comparing rituximab monotherapy with WW was performed in this population. PubMed, Embase, and Cochrane Library were systematically searched for studies comparing rituximab monotherapy with WW in adult patients with advanced-stage LTB-FL. The primary outcome was overall survival (OS), while secondary outcomes included histological transformation (HT) and time to new treatment (TTNT). Statistical analyses were conducted using Review Manager version 5.4 with random-effects models, and heterogeneity was assessed using the I² statistic. Three studies, including 2 randomized controlled trials and one observational study, comprising 1590 patients, were included. For OS, analysis demonstrated no statistically significant difference between rituximab and WW (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.70-1.12; P = .31; I² = 0%). Similarly, rituximab was not associated with a statistically significant reduction in HT (risk ratios 0.84, 95% CI 0.60-1.16; P = .29; I² = 0%), although the pooled estimates for OS and HT numerically favored rituximab. TTNT was significantly prolonged with rituximab compared with WW (HR 0.50, 95% CI 0.41-0.61; P < .00001; I² = 0%). Early rituximab monotherapy was not associated with improved OS or a significant reduction in HT compared with WW in asymptomatic patients with advanced-stage LTB-FL, although it prolonged TTNT. Further prospective studies are warranted to define the long-term clinical impact of early rituximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Rio de Janeiro State University, Rio de Janeiro, Brazil. Electronic address: hosanaminac@gmail.com.
- Department of Medicine, JSS Medical College, Mysore, India.
- Department of Internal Medicine, University of Colorado, Aurora, CO.
- Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/Elmhurst, New York, NY.
- Department of Hematology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
- Department of Internal Medicine, University of Hawai'i John A. Burns School of Medicine, Honolulu, HI.
Zitieren
APA
Candreva, H., Dang, M., Coelho, H. G. B., Jeong, Y., Alabbas, F., & Miyashita, A. (2026). Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia, 26(11), e1241-e1248.e1. https://doi.org/10.1016/j.clml.2026.09.009
Vancouver
Candreva H, Dang M, Coelho HGB, Jeong Y, Alabbas F, Miyashita A. Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia. 2026;26(11):e1241-e1248.e1. doi:10.1016/j.clml.2026.09.009
BibTeX
@article{Candreva2026,
author = {Candreva, Hosana and Dang, Mehak and Coelho, Henrique Guimarães Barbosa and Jeong, Yujin and Alabbas, Fahad and Miyashita, Akihiro},
title = {Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {11},
pages = {e1241--e1248.e1},
doi = {10.1016/j.clml.2026.09.009}
}
EUVIMED